Asukamycin contains a modified PKS scaffold and an electrophilic epoxide ring and has been shown to act as both a farsenyltransferase inhibitor and a molecular glue between the UBR7 E3 ubiquitin ligase and the TP53 tumor suppressor, leading to cell death (44, 45). Here, TP53 is linked to neoplasm.